» Articles » PMID: 35694437

Fatty Acid-binding Protein 5 (FABP5)-related Signal Transduction Pathway in Castration-resistant Prostate Cancer Cells: a Potential Therapeutic Target

Overview
Journal Precis Clin Med
Specialty General Medicine
Date 2022 Jun 13
PMID 35694437
Authors
Affiliations
Soon will be listed here.
Abstract

In this short communication, a novel fatty acid-binding protein 5 (FABP5)-related signal transduction pathway in prostate cancer is reviewed. In castration-resistant prostate cancer (CRPC) cells, the FABP5-related signal transduction pathway plays an important role during transformation of the cancer cells from androgen-dependent state to androgen-independent state. The detailed route of this signal transduction pathway can be described as follows: when FABP5 expression is increased as the increasing malignancy, excessive amounts of fatty acids from intra- and extra-cellular sources are transported into the nucleus of the cancer cells where they act as signalling molecules to stimulate their nuclear receptor peroxisome proliferator-activated receptor gamma (PPARγ). The phosphorylated or biologically activated PPARγ then modulates the expression of its downstream target regulatory genes to trigger a series of molecular events that eventually lead to enhanced tumour expansion and aggressiveness caused by an overgrowth of the cancer cells with a reduced apoptosis and an increased angiogenesis. Suppressing the FABP5-related pathway via RNA interference against FABP5 has produced a 63-fold reduction in the average size of the tumours developed from CRPC cells in nude mice, a seven-fold reduction of tumour incidence, and a 100% reduction of metastasis rate. Experimental treatments of CRPC with novel FABP5 inhibitors have successfully inhibited the malignant progression of CRPC cells both and in nude mouse. These studies suggest that FABP5-related signal transduction pathway is a novel target for therapeutic intervention of CRPC cells.

Citing Articles

Experimental treatment efficacy of dmrFABP5 on prostate cancer singly or in combination with drugs in use.

Abdulsamad S, Naeem A, Zeng H, He G, Jin X, Alenezi B Am J Cancer Res. 2024; 14(1):300-323.

PMID: 38323289 PMC: 10839311.


FABP5 Inhibition against -Mutant Therapy Resistant Prostate Cancer.

Swamynathan M, Mathew G, Aziz A, Gordon C, Hillowe A, Wang H Cancers (Basel). 2024; 16(1).

PMID: 38201488 PMC: 10871093. DOI: 10.3390/cancers16010060.


Caprylic Acid (FFA C8:0) promotes the progression of prostate cancer by up-regulating G protein-coupled receptor 84/ Krüppel-like factor 7.

Li X, Yuan C, Yang B, Pang H, Li W, Li M BMC Cancer. 2023; 23(1):426.

PMID: 37170248 PMC: 10173472. DOI: 10.1186/s12885-023-10841-2.


Temporal and sex-dependent gene expression patterns in a renal ischemia-reperfusion injury and recovery pig model.

Nemours S, Castro L, Ribatallada-Soriano D, Semidey M, Aranda M, Ferrer M Sci Rep. 2022; 12(1):6926.

PMID: 35484379 PMC: 9051203. DOI: 10.1038/s41598-022-10352-3.


The Biological Functions and Regulatory Mechanisms of Fatty Acid Binding Protein 5 in Various Diseases.

Xu B, Chen L, Zhan Y, S Marquez K, Zhuo L, Qi S Front Cell Dev Biol. 2022; 10:857919.

PMID: 35445019 PMC: 9013884. DOI: 10.3389/fcell.2022.857919.


References
1.
Chi Y, Nakamura M, Zhao X, Yoshizawa T, Yan W, Hashimoto F . Antinociceptive activities of alpha-truxillic acid and beta-truxinic acid derivatives. Biol Pharm Bull. 2006; 29(3):580-4. DOI: 10.1248/bpb.29.580. View

2.
Adamson J, Morgan E, Beesley C, Mei Y, Foster C, Fujii H . High-level expression of cutaneous fatty acid-binding protein in prostatic carcinomas and its effect on tumorigenicity. Oncogene. 2003; 22(18):2739-49. DOI: 10.1038/sj.onc.1206341. View

3.
Dunnington D, Hughes C, Monaghan P, Rudland P . Phenotypic instability of rat mammary tumor epithelial cells. J Natl Cancer Inst. 1983; 71(6):1227-40. View

4.
Forootan F, Forootan S, Malki M, Chen D, Li G, Lin K . The expression of C-FABP and PPARγ and their prognostic significance in prostate cancer. Int J Oncol. 2013; 44(1):265-75. DOI: 10.3892/ijo.2013.2166. View

5.
Ahmad I, Mui E, Galbraith L, Patel R, Tan E, Salji M . Sleeping Beauty screen reveals Pparg activation in metastatic prostate cancer. Proc Natl Acad Sci U S A. 2016; 113(29):8290-5. PMC: 4961202. DOI: 10.1073/pnas.1601571113. View